Dr. Eduardo Andre, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 221
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME109523
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hospital West Pembroke Pines, FL
- Memorial Hospital Miramar Miramar, FL
Medical groups
- Pulmonary Physicians of South Florida LLC (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 221
- Services billed
- 718
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 551 | 177 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 154 | 81 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 122 | 105 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 52 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Pembroke Pines, FL | 284 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Pembroke Pines, FL | 203 |
| Montelukast Sodium Other prescribers in Pembroke Pines, FL | 137 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pembroke Pines, FL | 135 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Pembroke Pines, FL | 127 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Pembroke Pines, FL | 76 |
| Fluticasone Propionate Other prescribers in Pembroke Pines, FL | 30 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Pembroke Pines, FL | 29 |
| Prednisone Other prescribers in Pembroke Pines, FL | 18 |
| Xarelto (rivaroxaban) Other prescribers in Pembroke Pines, FL | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $88,300 in research payments for these studies, mostly to the institutions running them.
- Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
AstraZeneca Pharmaceuticals LP - A randomized, double-blind, placebo-controlled, parallel-group, multic
GlaxoSmithKline, LLC. - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP - A multi-center, randomized, double-blind, parallel-group, placebo-cont
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.